TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Pro Medicus Limited ( (AU:PME) ) has shared an announcement.
Pro Medicus Limited announced the cessation of 47,930 performance rights due to unmet conditions, as of August 25, 2025. This development may affect the company’s capital structure and could have implications for stakeholders regarding the company’s performance metrics and future financial planning.
The most recent analyst rating on (AU:PME) stock is a Buy with a A$361.00 price target. To see the full list of analyst forecasts on Pro Medicus Limited stock, see the AU:PME Stock Forecast page.
More about Pro Medicus Limited
Pro Medicus Limited operates in the healthcare technology industry, providing advanced imaging software and services to medical professionals and institutions. The company focuses on delivering innovative solutions that enhance medical imaging capabilities and improve patient care.
YTD Price Performance: 22.62%
Average Trading Volume: 175,830
Technical Sentiment Signal: Buy
Current Market Cap: A$32.01B
See more data about PME stock on TipRanks’ Stock Analysis page.